Integrating clinical decision support systems in chronic kidney disease management

Chronic kidney disease (CKD) affects 10-14% of the population, contributing to significant morbidity and mortality worldwide. 1,2 Although there are therapies that reduce CKD-associated morbidity and mortality, CKD care is mired by critical gaps. 3 Albuminuria testing is underutilized, and key therapies proven to slow CKD progression, such as sodium-glucose cotransporter 2 inhibitors (SGLT2i), mineralocorticoid receptor antagonists (MRA), glucagon-like peptide-1 receptor agonists (GLP1-RA), alongside renin-angiotensin-aldosterone system inhibitors (RAASi), remain underprescribed 34.